Oligonucleotide (Antisense oligonucleotide) · developed by ELI LILLY &
LY3873862 is an antisense oligonucleotide that acts on SOD1 RNA to lower production of the superoxide dismutase 1 protein. It is studied in amyotrophic lateral sclerosis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07883590 | Phase 1 | Amyotrophic Lateral Sclerosis | Not yet recruiting | LLY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Amyotrophic Lateral SclerosisCytochrome P-450 Enzyme System
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →